Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene

Menopause

Volumn 16, Issue 4, 2009, Pages 785-791

  Nielsen, Mads ^a,b   Raundahl, Jakob ^a,b   Pettersen, Paola C ^c   Loog, Marco ^a,b   Karemore, Gopal ^a,b   Karsdal, Morten A ^b   Christiansen, Claus ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NORDIC BIOSCIENCE A S   (Denmark)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone markers; Breast density; Hormone treatment

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTRADIOL; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OBESITY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; BREAST; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 68449095622     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/GME.0b013e318199d07f     Document Type: Article

References (46)

1. Coldetz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998;90:814-823.
2. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
3. Yaffe M, Boyd N. Mammographie breast density and cancer risk: the radiological view. Gynecol Endocrinol 2005;21:6-11.
4. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236.
5. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001;38:103-113.
6. Conner P. Breast response to menopausal hormone therapy - aspects on proliferation, apoptosis and mammographie density. Ann Med 2007;39:28-41.
7. Kaewrudee S, Anuwutnavin S, Kanpittaya J, Soontrapa S, Sakondhavat C. Effect of estrogen-progestin and estrogen on mammographie density. J Reprod Med 2007;52:513-520.
8. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographie density. J Natl Cancer Inst 2003;95:30-37.
9. Schaller S, Henriksen K, Hoegh-Andersen P, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553-580.
10. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-1153.
11. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363-2368.
12. Sondergaard BC, Henriksen K, Wulf H, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006;14:738-748.
13. Nielsen RH, Stoop R, Leeming DJ, et al. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 2008;13:79-87.
14. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-2478.
15. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
16. Lasco A, Gaudio A, Morini E, et al. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 2006;13:787-792.
17. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographie breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003;188:389-394.
18. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographie density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1696-1701.
19. Cirpan T, Akercan F, Itil IM, Gundem G, Bilgen I, Yucebilgin MS. Does raloxifene therapy affect mammographie breast cancer screening in postmenopausal patients? Eur J Gynaecol Oncol 2006;27:177-178.
20. Schaefers M, Myysers C, Alexandersen P, Christiansen C. Effect of micro-dose transdermal 17-estradiol compared to raloxifene in prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. Menopause 2009;16:559-565.
21. Raundahl J. Mammographie Pattern Recognition [thesis/dissertation] . Denmark: University of Copenhagen; August 1, 2008.
22. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographie densities. Phys Med Biol 1994;39:1629-1638.
23. Raundahl J, Loog M, Pettersen P, Tanko LB, Nielsen M. Automated effect-specific mammographie pattern measures. IEEE Trans Med Imaging 2008;27:1054-1060.
24. Raundahl J, Loog M, Nielsen M. Understanding Hessian-based density scoring. In: Lecture Notes in Computer Science. Berlin: Springer-Verlag, 2006;4046:447-452.
25. Pettersen PC, Raundahl J, Loog M, Nielsen M, Tanko LB, Christiansen C. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms. Climacteric 2008;11:135-143.
26. American College of Radiology (ACR). Breast Imaging Reporting and Data System Atlas (BI-RADS® Atlas). Reston, VA; American College of Radiology, 2003.
27. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographie densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-1144.
28. Alowami S, Troup S, AI Haddad S, Kirkpatrick I, Watson PH. Mammographie density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003;5:R129-R135.
29. Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographie density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:343-349.
30. Vachon CM, Pankratz VS, Scott CG, et al. Longitudinal trends in mammographie percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:921-928.
31. Boyd NF, Martin LJ, Li Q, et al. Mammographie density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006;15:961-966.
32. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographie breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-395.
33. Stone J, Gurrin LC, Byrnes GB, et al. Mammographie density and candidate gene variants: a twins and sisters study. Cancer Epidemiol Biomarkers Prev 2007;16:1479-1484.
34. Vachon CM, Sellers TA, Carlson EE, et al. Strong evidence of a genetic determinant for mammographie density, a major risk factor for breast cancer. Cancer Res 2007;67:8412-8418.
35. Torres-Mejia G, De Stavola B, Allen DS, et al. Mammographie features and subsequent risk of breast cancer: a comparison of qualitative and quantitative evaluations in the Guernsey prospective studies. Cancer Epidemiol Biomarkers Prev 2005;14:1052-1059.
36. Li H, Giger ML, Olopade OI, Lan L. Fractal analysis of mammographie parenchymal patterns in breast cancer risk assessment. Acad Radiol 2007;14:513-521.
37. Nielsen M, Loog M, Raundahl J, et al. A novel and automatic heterogeneity examination of radiographs (HER) improved prediction of breast cancer. Submitted for publication. 2008.
38. Gapstur SM, Lopez P, Colangelo LA, Wolfman J, Van Horn L, Hendrick RE. Associations of breast cancer risk factors with breast density in Hispanic women. Cancer Epidemiol Biomarkers Prev 2003;12:1074-1080.
39. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000;11:653-662.
40. Caire-Juvera G, Arendell LA, Maskarinec G, Thomson CA, Chen Z. Associations between mammographie density and body composition in Hispanic and non-Hispanic white women by menopause status. Menopause 2008;15:319-325.
41. Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer 1998;78:1233-1238.
42. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003;107:1626-1631.
43. Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16:638-646.
44. Sorensen MG, Henriksen K, Dziegiel MH, Tanko LB, Karsdal MA. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 2006;25:475-483.
45. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003;70:257-262.
46. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956-1964.